ATE556712T1 - A2a antagonisten zur behandlung von motorischen störungen - Google Patents
A2a antagonisten zur behandlung von motorischen störungenInfo
- Publication number
- ATE556712T1 ATE556712T1 AT10005600T AT10005600T ATE556712T1 AT E556712 T1 ATE556712 T1 AT E556712T1 AT 10005600 T AT10005600 T AT 10005600T AT 10005600 T AT10005600 T AT 10005600T AT E556712 T1 ATE556712 T1 AT E556712T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonists
- treatment
- hydrogen atom
- motor disorders
- substituted
- Prior art date
Links
- 208000019430 Motor disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005166981 | 2005-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE556712T1 true ATE556712T1 (de) | 2012-05-15 |
Family
ID=37498474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT10005600T ATE556712T1 (de) | 2005-06-07 | 2006-06-07 | A2a antagonisten zur behandlung von motorischen störungen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7851478B2 (de) |
| EP (2) | EP1902716A4 (de) |
| JP (3) | JPWO2006132275A1 (de) |
| AT (1) | ATE556712T1 (de) |
| ES (1) | ES2385702T3 (de) |
| WO (1) | WO2006132275A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057855A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity |
| CA2750265A1 (en) * | 2009-01-20 | 2010-07-29 | Marc Cantillon | Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease |
| JP5765239B2 (ja) | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物 |
| TWI548411B (zh) * | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
| US8796290B2 (en) | 2009-11-09 | 2014-08-05 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| DK2531492T3 (en) | 2010-02-05 | 2016-07-04 | Heptares Therapeutics Ltd | 1,2,4-triazin-4-amine derivatives |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| JP6308346B2 (ja) * | 2013-05-31 | 2018-04-11 | 三菱自動車工業株式会社 | 車両の制御装置 |
| JP6381883B2 (ja) * | 2013-10-04 | 2018-08-29 | 国立大学法人千葉大学 | 不随意運動の予防及び／又は治療組成物 |
| WO2019123482A1 (en) | 2017-12-19 | 2019-06-27 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
| IL275817B2 (en) * | 2018-01-04 | 2024-04-01 | Impetis Biosciences Ltd | Tricyclic compounds, compositions and medicinal applications thereof |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| EP3810610A1 (de) * | 2018-05-18 | 2021-04-28 | Incyte Corporation | Kondensierte pyrimidinderivate als a2a/a2b-inhibitoren |
| AU2019297361B2 (en) | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| EP3950064A4 (de) * | 2019-04-03 | 2023-01-04 | Tera Stone Co., Ltd | Auf thyminnukleobase basierende triazolopyrimidine und verfahren zu ihrer herstellung |
| WO2022029063A1 (en) | 2020-08-04 | 2022-02-10 | Bayer Aktiengesellschaft | Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997027177A2 (en) | 1996-01-29 | 1997-07-31 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists |
| CA2284737C (en) | 1997-03-24 | 2007-03-13 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]triazolo[1,5-c]pyrimidine derivatives |
| AU2639299A (en) * | 1998-02-24 | 1999-09-15 | Kyowa Hakko Kogyo Co. Ltd. | Remedies/preventives for parkinson's disease |
| WO2000017201A1 (en) * | 1998-09-22 | 2000-03-30 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES |
| WO2000069464A1 (en) | 1999-05-12 | 2000-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| US20040152659A1 (en) | 1999-05-12 | 2004-08-05 | Fujisawa Pharmaceutical Co. Ltd. | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist |
| JP2001302648A (ja) * | 2000-04-28 | 2001-10-31 | Kyowa Hakko Kogyo Co Ltd | ピペラジン誘導体の製造法 |
| SI1283839T1 (de) | 2000-05-26 | 2005-08-31 | Schering Corp | |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| AR037243A1 (es) * | 2001-10-15 | 2004-11-03 | Schering Corp | Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| ES2283625T3 (es) * | 2001-11-30 | 2007-11-01 | Schering Corporation | Antagonistas del receptopr a2a de adenosina de (1,2,4)-triazol biciclicos. |
| US6916811B2 (en) * | 2001-11-30 | 2005-07-12 | Schering Corporation | Adenosine A2a receptor antagonists |
| DE10159922A1 (de) | 2001-12-06 | 2003-06-26 | Gruenenthal Gmbh | Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate |
| ES2686123T3 (es) | 2002-01-28 | 2018-10-16 | Kyowa Hakko Kogyo Co., Ltd | Antagonistas del receptor A2A para su uso en el tratamiento de trastornos del movimiento |
| AU2003304527B2 (en) | 2002-12-19 | 2010-09-09 | Merck Sharp & Dohme Corp. | Uses of adenosine A2a receptor antagonists |
| DE602004018637D1 (de) | 2003-04-09 | 2009-02-05 | Biogen Idec Inc | A2a-adenosinrezeptorantagonisten |
| EP1622912B1 (de) * | 2003-04-23 | 2009-05-27 | Schering Corporation | 2-alkinyl- und 2-alkenyl-pyrazolo-[4,3-e] -1,2,4-triazolo-[1,5-c] -pyrimidinadenosin a2a rezeptorantagonisten |
| PT1678182E (pt) * | 2003-10-28 | 2007-04-30 | Schering Corp | Processo para preparar 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pirimidinas |
| JP2007513091A (ja) * | 2003-12-01 | 2007-05-24 | シェーリング コーポレイション | 置換された５−アミノ−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ［１，５−ｃ］ピリミジンを調製するための方法 |
| CA2622741A1 (en) * | 2005-09-19 | 2007-03-29 | Schering Corporation | 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists |
-
2006
- 2006-06-07 EP EP06757137A patent/EP1902716A4/de not_active Withdrawn
- 2006-06-07 AT AT10005600T patent/ATE556712T1/de active
- 2006-06-07 WO PCT/JP2006/311430 patent/WO2006132275A1/ja not_active Ceased
- 2006-06-07 EP EP10005600A patent/EP2258372B8/de not_active Not-in-force
- 2006-06-07 US US11/916,783 patent/US7851478B2/en active Active
- 2006-06-07 ES ES10005600T patent/ES2385702T3/es active Active
- 2006-06-07 JP JP2007520141A patent/JPWO2006132275A1/ja active Pending
-
2012
- 2012-11-06 JP JP2012244147A patent/JP2013056911A/ja active Pending
-
2014
- 2014-08-27 JP JP2014172319A patent/JP2015007096A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2258372B1 (de) | 2012-05-09 |
| JPWO2006132275A1 (ja) | 2009-01-08 |
| JP2013056911A (ja) | 2013-03-28 |
| ES2385702T3 (es) | 2012-07-30 |
| WO2006132275A1 (ja) | 2006-12-14 |
| US20090105277A1 (en) | 2009-04-23 |
| US7851478B2 (en) | 2010-12-14 |
| EP1902716A4 (de) | 2009-05-13 |
| JP2015007096A (ja) | 2015-01-15 |
| EP2258372A1 (de) | 2010-12-08 |
| EP2258372B8 (de) | 2012-12-19 |
| EP1902716A1 (de) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2258372B8 (de) | A2A Antagonisten zur Behandlung von motorischen Störungen | |
| WO2005018557A3 (en) | Substituted pyridinones | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| PT1159279E (pt) | 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais | |
| MXPA05010621A (es) | Pirimidinonas sustituidas. | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| EP1700856A4 (de) | Thiazolderivat | |
| TW200615266A (en) | Organic compounds | |
| WO2005095384A8 (en) | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists | |
| DE602008004540D1 (de) | 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydroindolizin-3-yl)acetamidderivate und verwandte verbindungen als antipilzmittel | |
| EP1757594A4 (de) | Chinazolinderivat | |
| EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
| ATE450514T1 (de) | Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung | |
| WO2005111002A3 (de) | Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen | |
| IL186777A0 (en) | (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor | |
| ATE357917T1 (de) | Behandlung von dyskinesie durch mu-selektive opioidantagonisten | |
| CA2522813A1 (en) | 2-alkynyl-and 2-alkenyl-pyrazolo-¬4,3-e|-1,2,4-triazolo-¬1,5-c|-pyrimidine adenosine a2a receptor antagonists | |
| MX2009004314A (es) | Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos. | |
| WO2004022540A3 (en) | Pyridazinone and pyridone derivatives as adenosine antagonists | |
| WO2005090296A3 (en) | N-substituted benzene sulfonamides | |
| DK1725536T3 (da) | Imidazolin-derivater med CB1-antagonistisk aktivitet | |
| ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| WO2008136377A1 (ja) | 二環式複素環化合物 | |
| ATE480527T1 (de) | Thiadiazolinderivate zur krebsbehandlung |